# F01 in the Treatment of Autoimmune Diseases

> **NCT06208280** · PHASE1 · UNKNOWN · sponsor: **RenJi Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Autoimmune Diseases

## Interventions

- **DRUG:** After preconditioning with Fludarabine and Cyclophosphamide, F01 will be evaluated.

## Key facts

- **NCT ID:** NCT06208280
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-09
- **Primary completion:** 2025-01
- **Final completion:** 2025-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-01-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06208280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06208280, "F01 in the Treatment of Autoimmune Diseases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06208280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*